777 results match your criteria Glioblastoma Multiforme* Neurology

Gamma Irradiation Triggers Immune Escape in Glioma-Propagating Cells.

Cancers (Basel) 2022 May 31;14(11). Epub 2022 May 31.

Institute of Anatomy, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.

Glioblastoma multiforme is the most common and devastating form of brain tumor for which only palliative radio- and chemotherapy exists. Although some clinical studies on vaccination approaches have shown promising efficacy due to their potential to generate long-term immune surveillance against cancer cells, the evasion mechanisms preventing therapy response are largely uncharacterized. Here, we studied the response of glioblastoma-propagating cells (GPCs) to clinically relevant doses of γ radiation. Read More

View Article and Full-Text PDF

Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-]pyrimidine-Based Macrocycles.

J Med Chem 2022 Jun 24;65(11):7799-7817. Epub 2022 May 24.

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.

Serine/threonine kinase 17A (death-associated protein kinase-related apoptosis-inducing protein kinase 1─DRAK1) is a part of the death-associated protein kinase (DAPK) family and belongs to the so-called dark kinome. Thus, the current state of knowledge of the cellular function of DRAK1 and its involvement in pathophysiological processes is very limited. Recently, DRAK1 has been implicated in tumorigenesis of glioblastoma multiforme (GBM) and other cancers, but no selective inhibitors of DRAK1 are available yet. Read More

View Article and Full-Text PDF

Machine learning and bioinformatics approaches for classification and clinical detection of bevacizumab responsive glioblastoma subtypes based on miRNA expression.

Jian Shi

Sci Rep 2022 May 23;12(1):8685. Epub 2022 May 23.

Department of Neurology, Department of Veterans Affairs Medical Center, University of California, San Francisco, CA, 94121, USA.

For the precise treatment of patients with glioblastoma multiforme (GBM), we classified and detected bevacizumab (BVZ)-responsive subtypes of GBM and found their differential expression (DE) of miRNAs and mRNAs, clinical characteristics, and related functional pathways. Based on miR-21 and miR-10b expression z-scores, approximately 30% of GBM patients were classified as having the GBM BVZ-responsive subtype. For this subtype, GBM patients had a significantly shorter survival time than other GBM patients (p = 0. Read More

View Article and Full-Text PDF

Is Edema Zone Volume Associated With Ki-67 Index in Glioblastoma Patients?

Cureus 2022 Apr 18;14(4):e24246. Epub 2022 Apr 18.

Neurology, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, BRA.

Introduction Despite all the progress with genetic mapping and multimodal treatment, the prognosis of Glioblastoma multiforme (GBM) remains poor, with median overall survival (OS) of only 12 to 15 months. Several studies showed correlations between glioblastoma clinic and prognosis factors; however, it doesn`t occur with tumor radiological features. The purpose of this study is to determine possible correlations between the volumetric analysis of glioblastoma compartments and the proliferation index represented by Ki-67. Read More

View Article and Full-Text PDF

High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach.

Cancer Immunol Immunother 2022 May 23. Epub 2022 May 23.

Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea.

Background: Glioblastoma multiforme (GBM) is an aggressive malignant primary brain tumor. Wnt/β-catenin is known to be related to GBM stemness. Cancer stem cells induce immunosuppressive and treatment resistance in GBM. Read More

View Article and Full-Text PDF

Centrin 2: A Novel Marker of Mature and Neoplastic Human Astrocytes.

Front Cell Neurosci 2022 29;16:858347. Epub 2022 Apr 29.

Fondazione Pisana per la Scienza ONLUS, San Giuliano Terme, Italy.

As microtubule-organizing centers (MTOCs), centrosomes play a pivotal role in cell division, neurodevelopment and neuronal maturation. Among centrosomal proteins, centrin-2 (CETN2) also contributes to DNA repair mechanisms which are fundamental to prevent genomic instability during neural stem cell pool expansion. Nevertheless, the expression profile of CETN2 in human neural stem cells and their progeny is currently unknown. Read More

View Article and Full-Text PDF

Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme.

Front Pharmacol 2022 28;13:898679. Epub 2022 Apr 28.

Department of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, China.

Glioblastoma multiforme (GBM) is the most common type of malignant brain tumor, among which IDH1-wild type GBM has a poor prognosis. Recent studies have shown that ferroptosis-related genes (FRGs) are correlated with the development and progression of cancer. In GBM, the role of FRGs associated with IDH1 status as biological indicators and therapeutic targets remains to be clarified. Read More

View Article and Full-Text PDF

Novel Antibody-Peptide Binding Assay Indicates Presence of Immunoglobulins against EGFR Phospho-Site S1166 in High-Grade Glioma.

Int J Mol Sci 2022 May 2;23(9). Epub 2022 May 2.

Department of Neurology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.

We investigated the feasibility of detecting the presence of specific autoantibodies against potential tumor-associated peptide antigens by enriching these antibody-peptide complexes using Melon Gel resin and mass spectrometry. Our goal was to find tumor-associated phospho-sites that trigger immunoreactions and raise autoantibodies that are detectable in plasma of glioma patients. Such immunoglobulins can potentially be used as targets in immunotherapy. Read More

View Article and Full-Text PDF

Glioblastoma Multiforme With CDKN2A, Loss of PTEN and EGFR Amplification, and Diffuse Distant Organ Metastasis Treated With Six Lines of Therapy: A Case Report and Literature Review.

Cureus 2022 Apr 3;14(4):e23796. Epub 2022 Apr 3.

Department of Neurology, Yüksek İhtisas University Medical Park Ankara Hospital, Ankara, TUR.

In glioblastoma multiforme (GBM) cases, the tumor usually remains limited to the central nervous system in the expected disease course. Here, we discuss the case of a 41-year-old male patient who presented with extracranial spread, which has been reported in a limited number of cases in the literature. The patient received six lines of treatment including radiotherapy with temozolomide, irinotecan-bevacizumab combination, lomustine, erlotinib, everolimus, and weekly carboplatin-paclitaxel. Read More

View Article and Full-Text PDF

Survival after reoperation for recurrent glioblastoma multiforme: A prospective study.

Surg Oncol 2022 Jun 20;42:101771. Epub 2022 Apr 20.

Department of Neurosurgery, 10th Military Research Hospital and Polyclinic, 85-681, Bydgoszcz, Poland; Department of Neurosurgery and Neurology, Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń, M. Skłodowskiej-Curie 9, 85-094, Bydgoszcz, Poland.

Purpose: Glioblastoma multiforme (GBM) is the most common malignant brain tumor. Moreover, GBM recurs in nearly all patients. Although a standard STUPP protocol has been widely used for newly diagnosed GBM, no standard regimen has been established for recurrent patients. Read More

View Article and Full-Text PDF

Expression Profiles of HOXC6 Predict the Survival of Glioblastoma Patients and Correlate with Cell Cycle.

J Oncol 2022 6;2022:8656865. Epub 2022 Apr 6.

Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China.

The goal of this study was to investigate the homeobox (HOX) gene expression status and its prognostic value in glioblastoma multiforme (GBM) and to uncover the biological processes related to its expression. The prognostic value of HOX genes in GBM was systematically investigated by a genome-wide analysis of HOX gene expression profiles in GBM patient samples in The Cancer Genome Atlas (TCGA) project (microarray dataset) and validation datasets. Using the differentially expressed gene (DEG) analysis and a Cox regression model, we discovered that the HOXC6 could stratify patients into significantly different survival ( = 0. Read More

View Article and Full-Text PDF

Simultaneous Presentation of Glioblastoma Multiforme in Divorced Spouses.

Case Rep Oncol 2022 Jan-Apr;15(1):231-237. Epub 2022 Mar 14.

Department of Pathology, University of Saskatchewan, Royal University Hospital, Saskatoon, Saskatchewan, Canada.

High-grade gliomas are the most common primary brain tumors in adults. However, with an incidence of 4/100,000 per year, glioblastoma multiforme is uncommon enough to make simultaneous presentation of identical tumors in husband and wife exceedingly rare. We report the fourth couple in the literature presenting with malignant astrocytomas concurrently. Read More

View Article and Full-Text PDF

Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers.

Cancers (Basel) 2022 Mar 23;14(7). Epub 2022 Mar 23.

Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Glioblastoma, or glioblastoma multiforme (GBM, WHO Grade IV), is a highly aggressive adult glioma. Despite extensive efforts to improve treatment, the current standard-of-care (SOC) regimen, which consists of maximal resection, radiotherapy, and temozolomide (TMZ), achieves only a 12-15 month survival. The clinical improvements achieved through immunotherapy in several extracranial solid tumors, including non-small-cell lung cancer, melanoma, and non-Hodgkin lymphoma, inspired investigations to pursue various immunotherapeutic interventions in adult glioblastoma patients. Read More

View Article and Full-Text PDF

Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.

Neuroscience 2022 05 6;491:240-270. Epub 2022 Apr 6.

Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia. Electronic address:

Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest malignant types of primary astrocytoma with a poor prognosis. At present, the standard of care includes surgical tumor resection, followed by radiation therapy concomitant with chemotherapy and temozolomide. New developments and significant advances in the treatment of GBM have been achieved in recent decades. Read More

View Article and Full-Text PDF

Prognostic value of -methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

Neurooncol Adv 2022 Jan-Dec;4(1):vdac030. Epub 2022 Mar 1.

Department of Neurology, University of California, Los Angeles, California, USA.

Background: Patients with () mutant gliomas have been associated with longer survival time than those that are wild-type. Previous studies have shown the prognostic value of () promoter methylation for glioblastoma multiforme (GBM), which are predominantly wild-type. Little is known of the prognostic value of methylation status for mutant gliomas. Read More

View Article and Full-Text PDF

Early repeat resection for residual glioblastoma: decision-making among an international cohort of neurosurgeons.

J Neurosurg 2022 Apr 1:1-10. Epub 2022 Apr 1.

2Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Texas.

Objective: The importance of extent of resection (EOR) in glioblastoma (GBM) has been thoroughly demonstrated. However, few studies have explored the practices and benefits of early repeat resection (ERR) when residual tumor deemed resectable is unintentionally left after an initial resection, and the survival benefit of ERR is still unknown. Herein, the authors aimed to internationally survey current practices regarding ERR and to analyze differences based on geographic location and practice setting. Read More

View Article and Full-Text PDF

Use of Complementary and Integrative Medicine Among Patients With Glioblastoma Multiforme Seen at a Tertiary Care Center.

Glob Adv Health Med 2022 25;11:2164957X221078543. Epub 2022 Mar 25.

Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Background: Glioblastoma multiforme (GBM) is among the most aggressive and lethal tumors, with a median survival of 12-15 months. Many patients use complementary and integrative medicine (CIM) therapies to supplement their cancer treatment.

Objective: To determine the prevalence of CIM use and identify the most frequently used types of CIM in a cohort of patients with GBM seen at a tertiary care medical center in the United States. Read More

View Article and Full-Text PDF

Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion.

Nat Commun 2022 03 21;13(1):1511. Epub 2022 Mar 21.

Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA, 95817, USA.

Glioblastoma multiforme (GBM) remains the top challenge to radiotherapy with only 25% one-year survival after diagnosis. Here, we reveal that co-enhancement of mitochondrial fatty acid oxidation (FAO) enzymes (CPT1A, CPT2 and ACAD9) and immune checkpoint CD47 is dominant in recurrent GBM patients with poor prognosis. A glycolysis-to-FAO metabolic rewiring is associated with CD47 anti-phagocytosis in radioresistant GBM cells and regrown GBM after radiation in syngeneic mice. Read More

View Article and Full-Text PDF

Reclassification of Glioblastoma Multiforme According to the 2021 World Health Organization Classification of Central Nervous System Tumors: A Single Institution Report and Practical Significance.

Cureus 2022 Feb 1;14(2):e21822. Epub 2022 Feb 1.

General and Clinical Pathology/Forensic Medicine and Deontology, Medical University of Varna, Varna, BGR.

Introduction The 2021 World Health Organization (WHO) classification of tumors of the central nervous system (CNS) has introduced significant changes to tumor taxonomy. One of the most significant changes in the isolation of isocitrate dehydrogenase (IDH) mutant forms of glioblastoma multiforme (GBM) into separate entities, as well as no longer allowing for entries to be classified as not otherwise specified (NOS). As a result, this entity now includes only the most aggressive adult-type tumors. Read More

View Article and Full-Text PDF
February 2022

From a dysembryoplastic neuroepithelial tumor to a glioblastoma multiforme: Pitfalls of initial diagnosis on biopsy material, a case report.

Surg Neurol Int 2022 11;13:43. Epub 2022 Feb 11.

Department of Neurosurgery, Medicine Maastricht University Medical Center, Maastricht, Limburg, Netherlands.

Background: Ganglioglioma (GG) and dysembryoplastic neuroepithelial tumor (DNET) belong to the group of low-grade epilepsy-associated tumors (LEAT) and are the most prevalent tumor types found in patients undergoing epilepsy surgery. Histopathological differentiation between GG and DNET can be difficult on biopsies due to limited tumor tissue.

Case Description: Here, we present a rare case where a low-grade tumor was initially classified as DNET, based on biopsy findings and unfortunately dedifferentiated within 10 years into a glioblastoma multiforme. Read More

View Article and Full-Text PDF
February 2022

Case Report: H3K27M-Mutant Glioblastoma Simultaneously Present in the Brain and Long-Segment Spinal Cord Accompanied by Acute Pulmonary Embolism.

Front Oncol 2021 8;11:763854. Epub 2022 Feb 8.

Department of Neurology and Neuroscience Center, First Hospital of Jilin University, Changchun, China.

Background: Glioblastoma multiforme (GBM) is a highly malignant glioma that rarely presents as an infratentorial tumor. Multicentric (MC) gliomas involve lesions widely separated in space or time, and MC gliomas involving supra- and infratentorial brain regions are rare. In most cases, the infratentorial lesion is seen after surgical manipulation or radiation therapy; it is typically located in the cerebellum or the cervical region, manifesting as metastasis originating from the brain. Read More

View Article and Full-Text PDF
February 2022

Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging.

Nanotheranostics 2022 24;6(3):256-269. Epub 2022 Jan 24.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cell surface marker expression in tumors dictates the selection of therapeutics, therapy response, and survival. However, biopsies are invasive, sample only a small area of the tumor landscape and may miss significant areas of heterogeneous expression. Here, we investigated the potential of antibody-conjugated surface-enhanced resonance Raman scattering nanoparticles (SERRS-NPs) to depict and quantify high and low tumoral surface marker expression, focusing on the surface markers epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in an intracerebral and peripheral setting with an inter- and intratumoral comparison of Raman signal intensities. Read More

View Article and Full-Text PDF

The embryonic stem cell microenvironment inhibits mouse glioma cell proliferation by regulating the PI3K/AKT pathway.

Transl Cancer Res 2021 Jan;10(1):487-498

Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Background: Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous system, accounting for 48.6% of malignant tumors. The current standard treatment plan includes the widest range of safe surgical resection, supplemented by local brain radiotherapy and temozolomide concurrent chemotherapy; this can cause serious side effects. Read More

View Article and Full-Text PDF
January 2021

Metabolics risk factors in a New Zealand glioblastoma cohort.

Neurooncol Pract 2022 Feb 12;9(1):43-49. Epub 2021 Nov 12.

Neurology Department, Waikato General Hospital, Hamilton, Waikato, New Zealand.

Background: Glioblastoma multiforme (GBM) is the most aggressive form of glioma. There is growing recognition that mitochondrial metabolism plays a role in cancer development. Metabolic syndrome is a risk factor for several cancers; however, the prevalence in GBM patients in New Zealand (NZ) is unknown. Read More

View Article and Full-Text PDF
February 2022

A qualitative exploration of the feasibility and acceptability of Meaning-Centered Psychotherapy for Cancer Caregivers.

Palliat Support Care 2022 Jan 26:1-7. Epub 2022 Jan 26.

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.

Objective: Caregivers of patients with cancer are at significant risk for existential distress. Such distress negatively impacts caregivers' quality of life and capacity to serve in their role as healthcare proxies, and ultimately, contributes to poor bereavement outcomes. Our team developed Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C), the first targeted psychosocial intervention that directly addresses existential distress in caregivers. Read More

View Article and Full-Text PDF
January 2022

Metabolomic Phenotyping of Gliomas: What Can We Get with Simplified Protocol for Intact Tissue Analysis?

Cancers (Basel) 2022 Jan 9;14(2). Epub 2022 Jan 9.

Department of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru, 85-089 Bydgoszcz, Poland.

Glioblastoma multiforme is one of the most malignant neoplasms among humans in their third and fourth decades of life, which is evidenced by short patient survival times and rapid tumor-cell proliferation after radiation and chemotherapy. At present, the diagnosis of gliomas and decisions related to therapeutic strategies are based on genetic testing and histological analysis of the tumor, with molecular biomarkers still being sought to complement the diagnostic panel. This work aims to enable the metabolomic characterization of cancer tissue and the discovery of potential biomarkers via high-resolution mass spectrometry coupled to liquid chromatography and a solvent-free sampling protocol that uses a microprobe to extract metabolites directly from intact tumors. Read More

View Article and Full-Text PDF
January 2022

Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes.

J Neurooncol 2022 Feb 3;156(3):579-588. Epub 2022 Jan 3.

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.

Background: Quantitative image analysis using pre-operative magnetic resonance imaging (MRI) has been able to predict survival in patients with glioblastoma (GBM). The study explored the role of postoperative radiation (RT) planning MRI-based radiomics to predict the outcomes, with features extracted from the gross tumor volume (GTV) and clinical target volume (CTV).

Methods: Patients with IDH-wildtype GBM treated with adjuvant RT having MRI as a part of RT planning process were included in the study. Read More

View Article and Full-Text PDF
February 2022

Lichen-Derived Compounds and Extracts as Biologically Active Substances with Anticancer and Neuroprotective Properties.

Pharmaceuticals (Basel) 2021 Dec 10;14(12). Epub 2021 Dec 10.

Department of Pharmacognosy, Poznan University of Medical Sciences, Święcickiego 4, 60-781 Poznan, Poland.

Lichens are a source of chemical compounds with valuable biological properties, structurally predisposed to penetration into the central nervous system (CNS). Hence, our research aimed to examine the biological potential of lipophilic extracts of , , , and their major secondary metabolites, in the context of searching for new therapies for CNS diseases, mainly glioblastoma multiforme (GBM). The extracts selected for the study were standardized for their content of salazinic acid, evernic acid, and (-)-usnic acid, respectively. Read More

View Article and Full-Text PDF
December 2021

Differentiation of Cerebral Neoplasms with Vessel Size Imaging (VSI).

Clin Neuroradiol 2022 Mar 23;32(1):239-248. Epub 2021 Dec 23.

Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Purpose: Cerebral neoplasms of various histological origins may show comparable appearances on conventional Magnetic Resonance Imaging (MRI). Vessel size imaging (VSI) is an MRI technique that enables noninvasive assessment of microvasculature by providing quantitative estimates of microvessel size and density. In this study, we evaluated the potential of VSI to differentiate between brain tumor types based on their microvascular morphology. Read More

View Article and Full-Text PDF

Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma.

Strahlenther Onkol 2022 05 22;198(5):468-474. Epub 2021 Dec 22.

Department of Radiation Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.

Background And Purpose: Primary gliosarcoma (GS) is a rare variant of IDH-wildtype glioblastoma multiforme. We performed a single-center analysis to identify prognostic factors.

Patients And Methods: We analyzed the records of 26 patients newly diagnosed with primary WHO grade IV GS. Read More

View Article and Full-Text PDF